Search
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Real-World Evidence in NSCLC Guides Clinical Decisions
Register: Developments in GVHD Prevention and Treatment
Targeting NSCLC with Uncommon EGFR Mutations
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Real-World Evidence in NSCLC Guides Clinical Decisions
Register: Developments in GVHD Prevention and Treatment
Targeting NSCLC with Uncommon EGFR Mutations
Clinical
View More
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
OncView
Podcasts
Readout 360
Year in Review
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
OncView
Podcasts
Readout 360
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
All Journals
For Authors
Tumor Board
CME/CE
Resources
Contemporary Concepts
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Contemporary Concepts
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
eNewsletter
Print Subscription
eNewsletter
Print Subscription
Search
Spotlight
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Real-World Evidence in NSCLC Guides Clinical Decisions
Register: Developments in GVHD Prevention and Treatment
Targeting NSCLC with Uncommon EGFR Mutations
Clinical
See All >
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Colorectal Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Liso-Cel for Relapsed/Refractory LBCL in Second Line
home
Articles
View All >>
FDA Approves Liso-Cel for Second-Line Relapsed/Refractory LBCL
June 25, 2022 10:50 AM
Videos
View All >>
Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL
Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL